<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03636061</url>
  </required_header>
  <id_info>
    <org_study_id>OPP-002</org_study_id>
    <nct_id>NCT03636061</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease</brief_title>
  <official_title>Multicenter, Randomized, Controlled, Double-Masked Clinical Trial to Evaluate the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease (The ONSET-1 Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oyster Point Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oyster Point Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and effectiveness of OC-01 Nasal Spray&#xD;
      as compared to placebo on signs and symptoms of dry eye disease&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a Phase 2b, multicenter, randomized, double-masked, placebo controlled study&#xD;
      designed to evaluate the safety and efficacy of OC 01 nasal spray in adult subjects with DED.&#xD;
      The study randomized 182 subjects, at least 22 years of age, who had a physician's diagnosis&#xD;
      of dry eye disease and met all other study eligibility criteria to receive an application of&#xD;
      OC-01 or placebo twice daily (BID) for 4 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 15, 2018</start_date>
  <completion_date type="Actual">September 26, 2018</completion_date>
  <primary_completion_date type="Actual">September 26, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in Schirmer's Test Score From Baseline to 28 Days</measure>
    <time_frame>28 Days [Visit 1 (baseline) and Visit 5 (28 days)]</time_frame>
    <description>The primary end point was the change in anesthetized Schirmer's Test Score (STS) from baseline to 28 days in the study eye following treatment with OC-01. Schirmer's test score from 0-35 mm where a higher score is indicative of a better outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Eye Dryness Score From Baseline to Day 28</measure>
    <time_frame>28 days [Visit 1 (baseline and Visit 5 (28 days)]</time_frame>
    <description>Change in Eye Dryness Score from baseline to 28 days. Eye Dryness (EDS) on a Visual Analogue Scale (VAS) from 0 (no discomfort) to 100 (maximum discomfort) millimeters where a lower score is indicative of a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 21 in Eye Dryness Score at 5 Minutes Post Treatment in the CAE.</measure>
    <time_frame>21 days [Visit 1 (baseline) and Visit 4 (21 days)]</time_frame>
    <description>Change from baseline to Day 21 in Eye Dryness Score at 5 minutes post treatment in the CAE. Eye Dryness (EDS) on a Visual Analogue Scale (VAS) from 0 (no discomfort) to 100 (maximum discomfort) millimeters where a lower score is indicative of a better outcome.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">182</enrollment>
  <condition>Dry Eye Disease</condition>
  <arm_group>
    <arm_group_label>OC-01 Low Dose, 0.12 mg/mL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>OC-01 (varenicline) nasal spray, Low Dose, 0.12 mg/mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OC-01 Mid Dose, 0.6 mg/mL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>OC-01 (varenicline) nasal spray Mid dose, 0.6 mg/mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OC-01 High Dose, 1.2 mg/mL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>OC-01 (varenicline) nasal spray High dose, 1.2 mg/mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (vehicle) nasal spray</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OC-01 (varenicline) nasal spray</intervention_name>
    <description>OC-01 (varenicline) nasal spray</description>
    <arm_group_label>OC-01 High Dose, 1.2 mg/mL</arm_group_label>
    <arm_group_label>OC-01 Low Dose, 0.12 mg/mL</arm_group_label>
    <arm_group_label>OC-01 Mid Dose, 0.6 mg/mL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (vehicle) nasal spray</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have used and/or desired to use an artificial tear substitute for dry eye symptoms&#xD;
             within 6 months prior to Visit 1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have had any intraocular surgery (such as cataract surgery), extraocular surgery (such&#xD;
             as blepharoplasty) in either eye within three months or refractive surgery within&#xD;
             twelve months of Visit 1&#xD;
&#xD;
          -  Have a history or presence of any ocular disorder or condition in either eye that&#xD;
             would, in the opinion of the Investigator, likely interfere with the interpretation of&#xD;
             the study results or participant safety such as significant corneal or conjunctival&#xD;
             scarring; pterygium or nodular pinguecula; current ocular infection, conjunctivitis,&#xD;
             or inflammation not associated with dry eye; anterior (epithelial) basement membrane&#xD;
             corneal dystrophy or other clinically significant corneal dystrophy or degeneration;&#xD;
             ocular herpetic infection; evidence of keratoconus; etc. Blepharitis not requiring&#xD;
             treatment and mild meibomian gland disease that are typically associated with DED are&#xD;
             allowed.&#xD;
&#xD;
          -  Have a systemic condition or disease not stabilized or judged by the Investigator to&#xD;
             be incompatible with participation in the study or with the lengthier assessments&#xD;
             required by the study (e.g., current systemic infection, uncontrolled autoimmune&#xD;
             disease, uncontrolled immunodeficiency disease, history of myocardial infarction or&#xD;
             heart disease, etc.)&#xD;
&#xD;
          -  Have a known hypersensitivity to any of the procedural agents or study drug components&#xD;
&#xD;
          -  Have any condition or history that, in the opinion of the investigator, may interfere&#xD;
             with study compliance, outcome measures, safety parameters, and/or the general medical&#xD;
             condition of the subject&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Newport Beach</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indianapolis</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andover</name>
      <address>
        <city>Andover</city>
        <state>Massachusetts</state>
        <zip>01810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 15, 2018</study_first_submitted>
  <study_first_submitted_qc>August 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2018</study_first_posted>
  <results_first_submitted>August 13, 2021</results_first_submitted>
  <results_first_submitted_qc>October 21, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 25, 2021</results_first_posted>
  <disposition_first_submitted>May 14, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>October 21, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">October 25, 2021</disposition_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 11, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT03636061/Prot_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 4, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT03636061/SAP_003.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>OC-01 Low Dose, 0.12 mg/ml</title>
          <description>OC-01 0.12 mg/ml nasal spray BID for 28 days</description>
        </group>
        <group group_id="P2">
          <title>OC-01 Mid Dose, 0.6 mg/ml</title>
          <description>OC-01 0.6 mg/ml nasal spray BID for 28 days</description>
        </group>
        <group group_id="P3">
          <title>OC-01 High Dose, 1.2 mg/ml</title>
          <description>OC-01 1.2 mg/ml nasal spray BID for 28 days</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Placebo (vehicle) nasal spray</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="44"/>
                <participants group_id="P4" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="40"/>
                <participants group_id="P4" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>OC-01 Low Dose, 0.12 mg/mL</title>
          <description>OC-01 0.12 mg/ml nasal spray BID for 28 days</description>
        </group>
        <group group_id="B2">
          <title>OC-01 Mid Dose, 0.6 mg/mL</title>
          <description>OC-01 0.6 mg/ml nasal spray BID for 28 days</description>
        </group>
        <group group_id="B3">
          <title>OC-01 High Dose, 1.2 mg/mL</title>
          <description>OC-01 1.2 mg/ml nasal spray BID for 28 days</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Vehicle nasal spray</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="47"/>
            <count group_id="B2" value="48"/>
            <count group_id="B3" value="44"/>
            <count group_id="B4" value="43"/>
            <count group_id="B5" value="182"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.2" spread="12.7"/>
                    <measurement group_id="B2" value="66.5" spread="9.4"/>
                    <measurement group_id="B3" value="67.4" spread="10.6"/>
                    <measurement group_id="B4" value="64" spread="10.3"/>
                    <measurement group_id="B5" value="65.5" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="137"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="164"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="40"/>
                    <measurement group_id="B5" value="157"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="43"/>
                    <measurement group_id="B5" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Schirmer's Test Score</title>
          <description>Schirmer's test score from 0-35 mm where a higher score is indicative of a better outcome.</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.2" spread="3.1"/>
                    <measurement group_id="B2" value="4.8" spread="2.7"/>
                    <measurement group_id="B3" value="5.5" spread="3.0"/>
                    <measurement group_id="B4" value="4.5" spread="2.9"/>
                    <measurement group_id="B5" value="5.0" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in Schirmer's Test Score From Baseline to 28 Days</title>
        <description>The primary end point was the change in anesthetized Schirmer's Test Score (STS) from baseline to 28 days in the study eye following treatment with OC-01. Schirmer's test score from 0-35 mm where a higher score is indicative of a better outcome.</description>
        <time_frame>28 Days [Visit 1 (baseline) and Visit 5 (28 days)]</time_frame>
        <population>Subjects in ITT-LOCF population</population>
        <group_list>
          <group group_id="O1">
            <title>OC-01 Low Dose, 0.12 mg/mL</title>
            <description>OC-01 0.12 mg/ml nasal spray</description>
          </group>
          <group group_id="O2">
            <title>OC-01 Mid Dose, 0.6 mg/ML</title>
            <description>OC-01 0.6 mg/ml nasal spray</description>
          </group>
          <group group_id="O3">
            <title>OC-01 High Dose, 1.2 mg/mL</title>
            <description>OC-01 1.2 mg/ml nasal spray</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Vehicle nasal spray</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Schirmer's Test Score From Baseline to 28 Days</title>
          <description>The primary end point was the change in anesthetized Schirmer's Test Score (STS) from baseline to 28 days in the study eye following treatment with OC-01. Schirmer's test score from 0-35 mm where a higher score is indicative of a better outcome.</description>
          <population>Subjects in ITT-LOCF population</population>
          <units>score on a scale, mm</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" spread="1.26"/>
                    <measurement group_id="O2" value="11.7" spread="1.27"/>
                    <measurement group_id="O3" value="11.0" spread="1.39"/>
                    <measurement group_id="O4" value="3.2" spread="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Eye Dryness Score From Baseline to Day 28</title>
        <description>Change in Eye Dryness Score from baseline to 28 days. Eye Dryness (EDS) on a Visual Analogue Scale (VAS) from 0 (no discomfort) to 100 (maximum discomfort) millimeters where a lower score is indicative of a better outcome.</description>
        <time_frame>28 days [Visit 1 (baseline and Visit 5 (28 days)]</time_frame>
        <population>Subjects in the ITT-LOCF population. The overall number of participants is different because these outcomes were assessed ar different visits 7 days apart and some subjects were not able to attend the Day 21 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>OC-01 Low Dose, 0.12 mg/ml</title>
            <description>OC-01 0.12 mg/ml nasal spray</description>
          </group>
          <group group_id="O2">
            <title>OC-01 Mid Dose, 0.6 mg/ml</title>
            <description>OC-01 0.6 mg/ml nasal spray</description>
          </group>
          <group group_id="O3">
            <title>OC-01 High Dose, 1.2 mg/ml</title>
            <description>OC-01 1.2 mg/ml nasal spray</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Vehicle nasal spray</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Eye Dryness Score From Baseline to Day 28</title>
          <description>Change in Eye Dryness Score from baseline to 28 days. Eye Dryness (EDS) on a Visual Analogue Scale (VAS) from 0 (no discomfort) to 100 (maximum discomfort) millimeters where a lower score is indicative of a better outcome.</description>
          <population>Subjects in the ITT-LOCF population. The overall number of participants is different because these outcomes were assessed ar different visits 7 days apart and some subjects were not able to attend the Day 21 visit.</population>
          <units>score on a scale, mm</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.6" spread="3.63"/>
                    <measurement group_id="O2" value="-18.9" spread="3.67"/>
                    <measurement group_id="O3" value="-15.6" spread="4.02"/>
                    <measurement group_id="O4" value="-5.4" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 21 in Eye Dryness Score at 5 Minutes Post Treatment in the CAE.</title>
        <description>Change from baseline to Day 21 in Eye Dryness Score at 5 minutes post treatment in the CAE. Eye Dryness (EDS) on a Visual Analogue Scale (VAS) from 0 (no discomfort) to 100 (maximum discomfort) millimeters where a lower score is indicative of a better outcome.</description>
        <time_frame>21 days [Visit 1 (baseline) and Visit 4 (21 days)]</time_frame>
        <population>Subjects in the ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>OC-01 Low Dose, 0.12 mg/ml</title>
            <description>OC-01 0.12 mg/ml nasal spray</description>
          </group>
          <group group_id="O2">
            <title>OC-01 Mid Dose, 0.6 mg/ml</title>
            <description>OC-01 0.6 mg/ml nasal spray</description>
          </group>
          <group group_id="O3">
            <title>OC-01 High Dose, 1.2 mg/ml</title>
            <description>OC-01 1.2 mg/ml nasal spray</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Vehicle nasal spray</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 21 in Eye Dryness Score at 5 Minutes Post Treatment in the CAE.</title>
          <description>Change from baseline to Day 21 in Eye Dryness Score at 5 minutes post treatment in the CAE. Eye Dryness (EDS) on a Visual Analogue Scale (VAS) from 0 (no discomfort) to 100 (maximum discomfort) millimeters where a lower score is indicative of a better outcome.</description>
          <population>Subjects in the ITT population</population>
          <units>score on a scale, mm</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.1" spread="2.7"/>
                    <measurement group_id="O2" value="-16.0" spread="2.7"/>
                    <measurement group_id="O3" value="-18.4" spread="3.0"/>
                    <measurement group_id="O4" value="-4.4" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events were collected from the first dose of study drug administration until the final study visit at Visit 5 (28 days)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>OC-01 Low Dose, 0.12 mg/mL</title>
          <description>OC-01 0.12 mg/ml nasal spray</description>
        </group>
        <group group_id="E2">
          <title>OC-01 Mid Dose, 0.6 mg/mL</title>
          <description>OC-01 0.6 mg/ml nasal spray</description>
        </group>
        <group group_id="E3">
          <title>OC-01 High Dose, 1.2 mg/mL</title>
          <description>OC-01 1.2 mg/ml nasal spray</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Vehicle nasal spray</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (20.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (20.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular TEAEs</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Blepharospasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Conjunctival deposit</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Visual impairement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Instillation site irritation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="48"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="44"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="47"/>
                <counts group_id="E2" events="38" subjects_affected="38" subjects_at_risk="48"/>
                <counts group_id="E3" events="37" subjects_affected="37" subjects_at_risk="44"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="48"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="44"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="48"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="44"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Dysaesthesia pharynx</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Nasal dryness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jeffrey Nau</name_or_title>
      <organization>Oyster Point Pharma, Inc.</organization>
      <phone>609-382-9035</phone>
      <email>jnau@oysterpointrx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

